AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02322879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Treatment Period
Description: (duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
Study NCT02322879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: (duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
Study NCT02322879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Treatment Period
Description: (duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
Study NCT00671671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small Molecule Agent (PF-868554)
Description: Study drug will be administered 700mg BID in the fed state for three days.
Study NCT00671671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small Molecule Agent (PF-868554)
Description: Study drug will be given 450mg BID for a duration of 10 days.
Study NCT05405959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
Study NCT05405959 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio Tape
Description: The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
Study NCT03536546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Peer Mentor Intervention
Description: A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
Study NCT03536546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
Study NCT03715205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study NCT00995072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol and metoprolol succinate
Description: Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
Study NCT00995072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate and nebivolol
Description: Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
Study NCT03063294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Toolkit
Description: The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
Study NCT03063294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Toolkit
Description: The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
Study NCT03063294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance-based coaching
Description: The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
Study NCT04196426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education intervention about osteoporosis and calcium
Description: The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
Study NCT04196426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention about osteoporosis and calcium
Description: The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
Study NCT04663022 — intervention group
Intervention type: OTHER
Intervention: Dunn's sensory profile questionnaire
Description: all children will complete the Dunn Sensory Profile questionnaire
Study NCT04115111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab in monotherapy as second line treatment
Study NCT03758170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT03758170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT01911377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Study NCT01911377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for Injection
Study NCT03260868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine, 300 units per milliliter (U/mL)
Description: Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
Study NCT03260868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300 units per milliliter (U/mL)
Description: Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
Study NCT03260868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Description: Subcutaneous injection.
Study NCT03260868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Description: Subcutaneous injection.
Study NCT00826306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
Study NCT00826306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
Study NCT01763879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The PCV-VCV group
Description: During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study NCT01763879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The VCV-PCV group
Description: During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study NCT04049318 — intervention group
Intervention type: OTHER
Intervention: Education+ exercise (delivered digitally)
Description: The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
Study NCT00066482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
Study NCT00066482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC > 5,000/uL
Study NCT00066482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
Study NCT00066482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
Study NCT00066482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
Study NCT00066482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
Study NCT00066482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESNA
Description: Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
Study NCT03163355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a gelling agent
Description: Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
Study NCT03163355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a gelling agent
Description: Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
Study NCT00217646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study NCT03493230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quantification of BRAF and NRAS mutation
Description: Quantification of cell-free BRAF and NRAS mutations with digital PCR
Study NCT04035057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviorally Enhanced Training
Description: Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
Study NCT04035057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Didactic Training
Description: Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
Study NCT04285255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: opioids anaesthesia
Study NCT04285255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
Study NCT04285255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: alpha 2 agonist with sedative, analgesic effect
Study NCT04285255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane block
Description: Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
Study NCT04285255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: infusion of lidocaine 2%(1mg/kg/h)
Study NCT01592331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT01592331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single oral dose
Study NCT00282893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transluminal ballooning
Study NCT04902274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
Study NCT04902274 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
Study NCT00282893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: currently existing therapies for the treatment of vasospasm
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye + high dose inulin + low dose gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye + high dose inulin + low dose gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye + equal doses of inulin & gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye + equal doses of inulin & gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye + low dose inulin + high dose gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye + low dose inulin + high dose gluten
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large non-supplemented rye
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large non-supplemented rye
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small non-supplemented rye
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT01965210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small non-supplemented rye
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study NCT04902274 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy
Description: After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
Study NCT04902274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
Study NCT04038970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN019, 5mg/kg
Description: Solution, intravenous, 5 mg/kg
Study NCT04038970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN019, 10 mg/kg
Description: Solution, intravenous, 10 mg/kg
Study NCT04038970 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, intravenous, Placebo
Study NCT04038970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition